Research programme: DGAT-1 inhibitors - Pfizer

Drug Profile

Research programme: DGAT-1 inhibitors - Pfizer

Alternative Names: BAY-744113; PF-0441560

Latest Information Update: 19 Apr 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Pfizer
  • Class Antihyperlipidaemics; Obesity therapies
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 03 Aug 2009 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 07 Nov 2008 Pfizer exits research activities in the area of obesity
  • 30 Sep 2008 Discontinued - Preclinical for Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top